captopril has been researched along with urapidil in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (50.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Haerlin, R; Rosenthal, J | 3 |
| Radtke, H; Schook, CE; Thieme, G; Wurst, W | 1 |
| Zeigler, DW; Zimmerman, BG | 1 |
| Christ, B; Haerlin, R; Rosenthal, J; Schäfer, N; Wurst, W | 1 |
| Haerlin, R; Rosenthal, J; Schäfer, N; Solleder, P; Wurst, W | 1 |
| Wiechmann, HW | 1 |
| Zimmerman, BG | 1 |
| Dorszewski, A; Dorsźewski, B; Figulla, HR; Göhmann, E; Kreuzer, H; Werner, GS | 1 |
| Bur, A; Derhaschnig, U; Hirschl, MM; Laggner, AN; Vlcek, M; Woisetschläger, C | 1 |
| Batic-Mujanovic, O; Brkic, S; Karabasic, A; Ljuca, F; Mustafic, S; Salkic, S | 1 |
1 review(s) available for captopril and urapidil
| Article | Year |
|---|---|
Overview of clinical trials with urapidil.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Captopril; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Heart Rate; Humans; Infusions, Intravenous; Injections, Intravenous; Piperazines; Random Allocation; Time Factors | 1989 |
10 trial(s) available for captopril and urapidil
| Article | Year |
|---|---|
Therapeutic assessment of urapidil or angiotensin-converting enzyme inhibition in systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Captopril; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Random Allocation; Time Factors; Vascular Resistance | 1989 |
Overview of clinical trials with urapidil.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Captopril; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Heart Rate; Humans; Infusions, Intravenous; Injections, Intravenous; Piperazines; Random Allocation; Time Factors | 1989 |
Efficacy of urapidil in the management of essential hypertension. A comparison with captopril.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Random Allocation | 1988 |
Treatment of mild hypertension with urapidil or captopril.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Captopril; Clinical Trials as Topic; Dizziness; Female; Headache; Humans; Hypertension; Male; Middle Aged; Nausea; Piperazines | 1988 |
Efficacy of urapidil in the management of essential hypertension: a comparison with captopril.
Topics: Adult; Aged; Antihypertensive Agents; Captopril; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Random Allocation | 1988 |
[Hemodynamic effects of different antihypertensive combinations].
Topics: Acebutolol; Antihypertensive Agents; Captopril; Chronic Disease; Diuretics; Drug Evaluation; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Piperazines; Random Allocation; Sulfonamides; Time Factors | 1988 |
[Treatment of hypertension with alpha blockade or ACE inhibition. Multicenter double-blind study of urapidil versus captopril].
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Random Allocation | 1986 |
Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Enalapril; Exercise Tolerance; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Odds Ratio; Oxygen Consumption; Piperazines; Quality of Life; Survival Analysis; Vasodilation; Vasodilator Agents | 1997 |
Comparison of intravenous urapidil and oral captopril in patients with hypertensive urgencies.
Topics: Administration, Oral; Captopril; Female; Humans; Hypertension; Injections, Intravenous; Male; Middle Aged; Piperazines | 2006 |
Emergency Room Treatment of Hypertensive Crises.
Topics: Acute Disease; Administration, Intravenous; Administration, Sublingual; Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Bosnia and Herzegovina; Captopril; Emergency Service, Hospital; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Prospective Studies | 2015 |
8 other study(ies) available for captopril and urapidil
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effect of alpha 1-adrenoceptor blockade on blood pressure and iliac vascular resistance in normotensive and Goldblatt hypertensive dogs; influence of dietary salt and DOCA-salt.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Captopril; Desoxycorticosterone; Dogs; Female; Hypertension, Renovascular; Iliac Artery; Male; Phenylephrine; Piperazines; Prazosin; Regional Blood Flow; Sodium, Dietary; Vascular Resistance | 1987 |
Determination of role of sympathetic and renin-angiotensin systems in Goldblatt hypertension with urapidil and captopril.
Topics: Animals; Blood Pressure; Captopril; Dogs; Female; Heart Rate; Hypertension, Renovascular; Kidney; Male; Norepinephrine; Piperazines; Proline; Renal Circulation; Renin; Renin-Angiotensin System; Sympathetic Nervous System; Vascular Resistance | 1984 |